|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu J, Latif S and Wei S: Metastatic renal
cell carcinoma presenting as gastric polyps: A case report and
review of the literature. Int J Surg Case Rep. 3:601–604. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geissler K, Fornara P, Lautenschlager C,
Holzhausen HJ, Seliger B and Riemann D: Immune signature of tumor
infiltrating immune cells in renal cancer. Oncoimmunology.
4:e9850822015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu W, Atkins MB and McDermott DF:
Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol.
17:137–150. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantia CM and McDermott DF: Vascular
endothelial growth factor and programmed death-1 pathway inhibitors
in renal cell carcinoma. Cancer. 125:4148–4157. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Oostveen J, Bijl J, Raaphorst F,
Walboomers J and Meijer C: The role of homeobox genes in normal
hematopoiesis and hematological malignancies. Leukemia.
13:1675–1690. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abate-Shen C: Deregulated homeobox gene
expression in cancer: Cause or consequence? Nat Rev Cancer.
2:777–785. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lou Y, Fallah Y, Yamane K and Berg PE:
BP1, a potential biomarker for breast cancer prognosis. Biomark
Med. 12:535–545. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM,
Qin Y, Liang RR, Leung TH, Xu D, Chan KK, et al: DLX1 acts as a
crucial target of FOXM1 to promote ovarian cancer aggressiveness by
enhancing TGF-β/SMAD4 signaling. Oncogene. 36:1404–1416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun B, Fan Y, Yang A, Liang L and Cao J:
MicroRNA-539 functions as a tumour suppressor in prostate cancer
via the TGF-β/Smad4 signalling pathway by down-regulating DLX1. J
Cell Mol Med. 23:5934–5948. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yilmaz M, Maass D, Tiwari N, Waldmeier L,
Schmidt P, Lehembre F and Christofori G: Transcription factor Dlx2
protects from TGFβ-induced cell-cycle arrest and apoptosis. EMBO J.
30:4489–4499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Green WJ, Ball G, Hulman G, Johnson C, Van
Schalwyk G, Ratan HL, Soria D, Garibaldi JM, Parkinson R, Hulman J,
et al: KI67 and DLX2 predict increased risk of metastasis formation
in prostate cancer-a targeted molecular approach. Br J Cancer.
115:236–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palazzo E, Kellett M, Cataisson C, Gormley
A, Bible PW, Pietroni V, Radoja N, Hwang J, Blumenberg M, Yuspa SH
and Morasso MI: The homeoprotein DLX3 and tumor suppressor p53
co-regulate cell cycle progression and squamous tumor growth.
Oncogene. 35:3114–3124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu B, Wang Q, Wang YA, Hua S, Sauvé CG,
Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, et al: Epigenetic
activation of WNT5A drives glioblastoma stem cell differentiation
and invasive growth. Cell. 167:1281–1295.e18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trinh BQ, Barengo N, Kim SB, Lee JS,
Zweidler-McKay PA and Naora H: The homeobox gene DLX4 regulates
erythro-megakaryocytic differentiation by stimulating IL-1β and
NF-κB signaling. J Cell Sci. 128:3055–3067. 2015.PubMed/NCBI
|
|
21
|
Haria D, Trinh BQ, Ko SY, Barengo N, Liu J
and Naora H: The homeoprotein DLX4 stimulates NF-κB activation and
CD44-mediated tumor-mesothelial cell interactions in ovarian
cancer. Am J Pathol. 185:2298–2308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Cerise J, Jabbari A, Clynes R and
Christiano A: Master regulators of infiltrate recruitment in
autoimmune disease identified through network-based molecular
deconvolution. Cell Syst. 1:326–337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hinrichs AS, Raney BJ, Speir ML, Rhead B,
Casper J, Karolchik D, Kuhn RM, Rosenbloom KR, Zweig AS, Haussler D
and Kent WJ: UCSC data integrator and variant annotation
integrator. Bioinformatics. 32:1430–1432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sing T, Sander O, Beerenwinkel N and
Lengauer T: ROCR: Visualizing classifier performance in R.
Bioinformatics. 21:3940–3941. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qu Y, Zhao R, Zhang H, Zhou Q, Xu F, Zhang
X, Xu W, Shao N, Zhou S, Dai B, et al: Inactivation of the
AMPK-GATA3-ECHS1 pathway induces fatty acid synthesis that promotes
clear cell renal cell carcinoma growth. Cancer Res. 80:319–333.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ge S, Hua X, Chen J, Xiao H, Zhang L, Zhou
J, Liang C and Tai S: Identification of a costimulatory
molecule-related signature for predicting prognostic risk in
prostate cancer. Front Genet. 12:6663002021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Charoentong P, Finotello F, Angelova M,
Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer
immunogenomic analyses reveal genotype-immunophenotype
relationships and predictors of response to checkpoint blockade.
Cell Rep. 18:248–262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abida W, Cheng ML, Armenia J, Middha S,
Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF,
et al: Analysis of the prevalence of microsatellite instability in
prostate cancer and response to immune checkpoint blockade. JAMA
Oncol. 5:471–478. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leibovich BC, Lohse CM, Crispen PL,
Boorjian SA, Thompson RH, Blute ML and Cheville JC: Histological
subtype is an independent predictor of outcome for patients with
renal cell carcinoma. J Urol. 183:1309–1315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Panganiban G and Rubenstein JL:
Developmental functions of the Distal-less/Dlx homeobox genes.
Development. 129:4371–4386. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Popovici C, Leveugle M, Birnbaum D and
Coulier F: Homeobox gene clusters and the human paralogy map. FEBS
Lett. 491:237–242. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Wan Y, Jiang Y, Zhang Z, Shu S,
Cheng W and Lang J: Overexpression of BP1, an isoform of Homeobox
Gene DLX4, promotes cell proliferation, migration and predicts poor
prognosis in endometrial cancer. Gene. 707:216–223. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu M, Yang Y, Shi Y, Wang D, Wei X, Zhang
N and Niu R: Expression level of beta protein 1 mRNA in Chinese
breast cancer patients: A potential molecular marker for poor
prognosis. Cancer Sci. 99:173–178. 2008.PubMed/NCBI
|
|
39
|
Man YG, Schwartz A, Levine PH, Teal C and
Berg PE: BP1, a putative signature marker for inflammatory breast
cancer and tumor aggressiveness. Cancer Biomark. 5:9–17. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Yang M, Gan L, He T, Xiao X,
Stewart MD, Liu X, Yang L, Zhang T, Zhao Y and Fu J: DLX4
upregulates TWIST and enhances tumor migration, invasion and
metastasis. Int J Biol Sci. 8:1178–1187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schwartz AM, Man YG, Rezaei MK, Simmens SJ
and Berg PE: BP1, a homeoprotein, is significantly expressed in
prostate adenocarcinoma and is concordant with prostatic
intraepithelial neoplasia. Mod Pathol. 22:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun Y, Lu X, Yin L, Zhao F and Feng Y:
Inhibition of DLX4 promotes apoptosis in choriocarcinoma cell
lines. Placenta. 27:375–383. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun G, Ge Y, Zhang Y, Yan L, Wu X, Ouyang
W, Wang Z, Ding B, Zhang Y, Long G, et al: Transcription factors
BARX1 and DLX4 contribute to progression of clear cell renal cell
carcinoma via promoting proliferation and epithelial-mesenchymal
transition. Front Mol Biosci. 8:6263282021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pallasch F and Schumacher U: Angiotensin
Inhibition, TGF-β and EMT in cancer. Cancers. 12:27852020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M,
Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A,
et al: Tumor immune microenvironment characterization in clear cell
renal cell carcinoma identifies prognostic and
immunotherapeutically relevant messenger RNA signatures. Genome
Biol. 17:2312016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vuong L, Kotecha R, Voss M and Hakimi A:
Tumor Microenvironment dynamics in clear-cell renal cell carcinoma.
Cancer Discov. 9:1349–1357. 2019. View Article : Google Scholar : PubMed/NCBI
|
